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Immunosuppression in elderly recipients has been underappreciated in clinical trials. Here, we assessed age-specific effects of the calcineurin inhibitor tacrolimus (TAC) in a murine transplant model and assessed its clinical relevance on human T cells. Old recipient mice exhibited prolonged skin graft survival compared with young animals after TAC administration. More important, half of the TAC dose was sufficient in old mice to achieve comparable systemic trough levels. TAC administration was able to reduce proinflammatory interferon-c cytokine production and promote interleukin-10 production in old CD4 + T cells. In addition, TAC administration decreased interleukin-2 secretion in old CD4 + T cells more effectively while inhibiting the proliferation of CD4 + T cells in old mice. Both TAC-treated murine and human CD4 + T cells demonstrated an age-specific suppression of intracellular calcineurin levels and Ca 2+ influx, two critical pathways in T cell activation. Of note, depletion of CD8 + T cells did not alter allograft survival outcome in old TAC-treated mice, suggesting that TAC age-specific effects were mainly CD4 + T cell mediated. Collectively, our study demonstrates age-specific immunosuppressive capacities of TAC that are CD4 + T cell mediated. The suppression of calcineurin levels and Ca 2+ influx in both old murine and human T cells emphasizes the clinical relevance of age-specific effects when using TAC.
Introduction
Demographic changes and improved longevity have given rise to a growing elderly patient population receiving or awaiting organ transplants (1) . The incidence of irreversible end organ damage in older patients has markedly increased during the past decades, and the majority of transplant recipients and organ donors is currently older than 50 years (2) . While benefits of organ transplantation in older patients have been established, there is a higher risk for infections, cardiovascular diseases, or malignancies, all exacerbated by immunosuppressive therapies (3, 4) . Clinical trials have mostly excluded older transplant recipients, and relevant aspects of immunosuppression have thus not been addressed sufficiently. Indeed, a meta-analysis of >500 studies revealed that trial participants who underwent kidney transplantation were significantly younger than the overall kidney transplant recipients in the United States (5) . Moreover, recognizing the necessity to respond to the rapid demographic shift, the US Food and Drug Administration recently encouraged clinical trials in the elderly (6) to explore age-specific aspects of immunosuppressants.
Although functional implications of immunosenescence have been explored extensively, age-specific effects of tacrolimus (TAC) in organ transplantation remain unclear (7) . With aging, phenotypic and functional changes such as an increase in the number CD4 + T cells that lack CD28 surface expression lead to compromised responses of T cells to antigens linked to impaired interaction between T cell receptor and antigen (8, 9) . Consequently, old T cells are only partially activated or remain in an anergic state (10) . Overall, lower rates of na€ ıve T cells along with a shift toward memory and effector CD4 + and CD8 + T cell populations are characteristic in aging (11, 12) . Clinically, we have previously shown that older recipients have reduced frequencies of acute rejections in parallel to an augmented susceptibility to immunosuppressants (13) .
Age-specific pharmacokinetic aspects of tacrolimus (TAC) have been explored recently. A prospective clinical trial has shown that kidney transplant recipients older than 65 years required only half of a body weight-adjusted dosage to achieve therapeutic trough levels (14) . Those age-dependent trough levels may be explained by an augmented first-pass metabolism of TAC linked to a decline of hepatic cytochrome P450 by approximately 8% with every decade of life (15) .
Here, we addressed age-specific aspects of TAC in a fully MHC-mismatched skin transplantation model and confirmed the clinical relevance of our findings in human T cells. 
Materials and Methods

Animals
Skin transplantation
Fully mismatched skin transplantations were performed; in detail, fullthickness skin grafts (1 cm 2 ) were removed from the tail of young DBA/2 mice and engrafted onto the dorsolateral thoracic wall of young and old C57BL/6 mice. Graft rejection was defined as necrosis exceeding 90%.
Tacrolimus (FK506)
TAC (Invitrogen, Carlsbad, CA) was dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO) and diluted with phosphate-buffered saline (PBS). TAC was administered intraperitoneally every 12 h; TAC trough levels were measured with the use of liquid chromatography-mass spectrometry. The area under the curve (AUC) was estimated by a trapezoidal rule applying the arithmetic means at each time point of the elimination phase (by 1, 4, 8, and 12 h) with t as the time point of administration, k denoting sampling times, y j representing the mean of the sample response, and Dt j ¼ ðt jþs À t j Þ:
Isolation of murine cells under a 5% CO 2 and 95% air atmosphere with saturated humidity. CD4 + T cells were cultured in coated wells with 10 lg/mL anti-mouse a-CD3 and 2 lg/mL soluble anti-mouse a-CD28 (both from eBioscience, San Diego, CA). Splenocytes were stimulated with 10 ng/mL lipopolysaccharide. TAC was dissolved in DMSO and diluted in PBS.
To determine absolute numbers of viable lymphocytes, trypan staining was performed and live cells were counted by using a hemocytometer (850 FS; Drew Scientific, Dallas, TX). In addition, flow cytometry was used with an a priori defined sample flow rate and sample volume to assess absolute numbers of T cell subtypes.
T helper type 1 cell-polarizing conditions
Na€ ıve CD4 + T cells were cultured in T helper type 1 cell (Th1)-polarizing conditions for 96 h. The following antibodies were used for murine cells: 50 ng/mL recombinant mouse interleukin (IL)-2, 50 ng/mL recombinant mouse IL-12, and 10 lg/mL anti-mouse IL-4 (all from eBioscience); for human cells, we used 50 ng/mL recombinant human IL-2, 50 ng/mL recombinant human IL-12, and 10 lg/mL anti-human IL-4 (all from eBioscience). As controls, na€ ıve CD4 + T cells were cultured with recombinant mouse IL-2 (50 ng/mL) to maintain T cell survival. After 96 h, supernatant and murine cells were analyzed by enzyme-linked immunosorbent assay (ELISA) and flow cytometry, respectively. After 12 days, supernatant and human cells were analyzed by ELISA and flow cytometry, respectively.
T cell proliferation
The proliferation of CD4 + T cells was determined by carboxyfluorescein succinimidyl ester (CFSE) dilution (eBioscience). Briefly, CFSE was dissolved in DMSO to a final stock solution of 10 mmol/L and then reuspended to 10 6 cells/mL at a concentration of 1 lmol/L. Cells were incubated for 10 min at room temperature, then for 5 min at 4°C and plated subsequently. Fluorescence of CFSE-stained cells was assessed by flow cytometry with a peak excitation of 494 nm and peak emission of 521 nm (FACS Canto II, Becton Dickinson, Franklin Lakes, NJ).
Flow cytometry
Cells were labeled with fluorescence antibodies for mouse a-CD4, a-CD8, a-interferon (INF)c, a-IL-2, a-IL-10, a-IL-4, a-IL-17A, a-CD44, and a-CD62L (eBioscience). To assess immune responses after transplantation, total splenocytes or isolated CD4 + T cells were seeded onto 48-well plates and stimulated in complete media for 4 h at 37°C with phorbol 12-myristate 13-acetate (PMA; 50 ng/mL; Sigma-Aldrich), ionomycin (500 ng/ mL; Sigma-Aldrich), and Brefeldin A (eBioscience). Thereafter, cells were fixed, permeabilized, and stained with respective antibodies at a concentration of 1-5 lg per 10 6 cells. Flow cytometry measurements were performed on a FACS Canto II (Becton Dickinson), and data were analyzed using FlowJo (FlowJo Software, Ashland, OR).
Elisa
Th1 (IL-2 and INFc), Th2 (IL-10 and IL-4), and Th17 (IL-17) specific cytokines were measured by using commercial ELISA kits (eBioscience) according to the manufacturer's instructions.
Enzyme-linked immunospot
Splenocytes were obtained from young and old C57BL/6 mice 7 days after transplantation and subsequently cultured in the presence of na€ ıve splenocytes from DBA/2 (H2 d ) for 48 h. Enzyme-linked immunospot (ELI-SPOT) testing was performed as described previously (17) . Spots were determined by a computer-assisted ELISPOT image analyzer (Cellular Technology, Cleveland, OH). 
Calcineurin and calcium assay
CD8 + T cell depletion
Young and old C57BL/6 skin transplant recipients received intravenous (tail vein) administration of 100 lg anti-mouse a-CD8 monoclonal purified antibody (Clone 53-6.7; Biolegend) every other day starting at the day of transplantation. Treatment resulted in reliable depletion of >90% of CD8 + T cells in recipient mice (Figure 8 ).
Statistics
Differences between groups were analyzed by using the Mann-Whitney U test with Bonferroni correction. Graft survival was compared by logrank test. A value of p < 0.05 was considered significant (*p < 0.05, **p < 0.01, ***p < 0.001).
Results
TAC-treated old recipient mice exhibit prolonged graft survival
To explore the efficacy of TAC in immunosenescence and to examine age-dependent rejection rates, skin grafts from young DBA/2 (H2 d ) mice were transplanted onto young and old C57BL/6 (H2 b ) mice. Consistent with our previous experimental work (18) , older, untreated recipients exhibited a prolonged graft survival compared with young animals ( Figure 1A ). Of particular relevance, when old and young recipients received weight-adapted doses of TAC, the majority of older recipients survived until the end of the observation period (day 30) while young animals rejected allografts by day 11 (mean survival time; n = 7; p < 0.0004; Figure 1B ). Of note, weight-dosed TAC resulted into significantly elevated trough levels in old recipients ( Figure 1C ). With therapeutic TAC levels, achieved when applying only 50% of a weight-adapted dose in older recipients (0.25 mg/kg compared with 0.5 mg/kg in young mice [ Figure S1 ]), old mice retained their skin grafts significantly longer. However, prolongation of graft survival was less pronounced (p = 0.0024; Figure 1D) . Collectively, these results suggested that TAC enhances allograft survival in an age-specific manner.
TAC enhances immunosuppressive responses in old CD4
+ T cells CD4 + T cells constitute a major subset that plays a critical role in alloimmune responses and allograft rejection (19, 20) . We have previously shown that aging alters frequencies of CD4 + T cell populations. In line with other groups, we found that aging is associated with a decline in na€ ıve and increased frequencies of effector/memory CD4 + T cells in both clinical and experimental models (17, 18, 21) . Thus, we assessed in vivo whether TAC administration altered CD4 + T cell populations. Following skin transplantation and TAC treatment, old mice exhibited higher frequencies of CD4 + CD44 high CD62L low effector/memory T cells, while frequencies of na€ ıve CD4 + CD44 low CD62L high T cells declined ( Figure 2 ). Of note, those age-specific effects were not affected when CD8 + T cells had been depleted. Taken together, our results suggest that TAC promotes allograft survival in old mice without targeting effector/ memory CD4 + T cell populations.
It is well established that CD4 + T cell differentiation and cytokine profiles play a critical role in regulating immune responses (22) . Indeed, IFNc is critical in augmenting alloimmune responses and allograft rejection, while IL-10 has been linked to less vigorous alloimmunity and prolonged allograft survival (23) . More important, IFNcproducing cells that coexpress IL-10 have displayed immunosuppressive properties (24) . We therefore focused on the effects of TAC on old CD4 + T cells and tested whether the observed prolongation of graft survival in old mice was linked to a modified balance of IFNc and IL-10 production by CD4 + T cells. Old and young mice underwent fully MHC-mismatched skin transplants, and systemic IFNc and IL-10 production was quantified by flow cytometry. ELISPOT analysis indicated a dramatic decrease in IFNc production in both young and old animals after TAC administration ( Figure 3A ). More important, flow cytometry analysis indicated that frequencies and ratios of CD4 + IL-10 + IFNc À cells were significantly elevated in old, TAC-treated animals (Figures 3B and C) . The enhanced suppression of IFNc in old CD4 + T cells and decreased secretion of IL-10 in young CD4 + T cells subsequent to TAC treatment was also confirmed by ELISA ( Figure S2 ). Next, we assessed the role of TAC on T cell differentiation and the capacity of TAC to regulate IFNc and IL-10 production in vitro. Consistent with our previous findings, IFNc production by CD4 + T cells isolated from young and old animals exposed to Th1-polarizing conditions had been effectively suppressed by TAC ( Figure 4A ). Moreover, frequencies of old CD4
+ IL-10 + T cells increased dramatically when TAC had been added ( Figure 4B ). Collectively, those data suggest that TAC exerts age-specific effects on IFNc and IL-10 cytokine production that promote immunosuppressive responses in old CD4 + T cells.
Age-dependent effects of TAC on IL-2 production and CD4 + T cell proliferation Previous studies have reported on age-specific changes of thymic output and repopulation of T cells linked to alterations of cytokine production (25) . Indeed, IL-2 has been shown to have an age-dependent expression that critically maintains CD4 + T cell activation and proliferation (26) . Therefore, we determined the systemic secretion of IL-2 that is known to maintain CD4 + T cell activation and proliferation. Total splenocytes isolated from untreated D a y s a fte r T x P e rc e n t s u rv iv a l Old recipients required only half of the weight-adapted dose (n = 5 per group) to reach comparable, age-matched trough levels. Graft survival was significantly prolonged in old recipients receiving weight-adjusted TAC doses. Age-differences in graft survival remained, albeit less pronounced, when TAC was applied based on trough levels. Statistics: mean AE SD; *p < 0.05, **p < 0.01. Log-rank test was used to compare graft survival; Mann-Whitney U test was used to compare groups.
old animals exhibited a decline in IL-2 secretion that was enhanced by TAC in an age-specific fashion ( Figure 5A ). To further dissect the impact of TAC on IL-2 production, we performed fully mismatched skin transplants in old and young animals and analyzed the production of IL-2 by CD4 + T cells. As shown in Figure 5 (B), TAC inhibited IL-2 production in vivo in an age-specific manner. Old animals treated with TAC demonstrated compromised IL-2 secretion. Moreover, reduced IL-2 secretion was associated with a reduced proliferation of old CD4 + T cells (Figures 6 and S3) . Interestingly, inhibitory effects of TAC were significantly more pronounced in purified old CD4 + T cells, suggesting compensatory effects in unseparated splenocytes ( Figure S3 ). Taken together, these results indicate that TAC inhibits CD4 + T cell proliferation and IL-2 secretion in an age-specific fashion.
Age-dependent effects on Ca
2+ /calmodulindependent calcineurin activity by TAC Next, we assessed Ca 2+ influx and calcineurin levels, both known to play a central role in nuclear factor of activated Tcells (NFAT) activation, a major downstream pathway of T cell receptor activation (27) . Na€ ıve CD4 + T cells were isolated from splenocytes of young and old mice and cultured under Th1-polarizing conditions and in the presence of a-CD3/a-CD28. Our ELISA showed that intracellular concentrations of calcineurin were significantly reduced in old CD4 + T cells ( Figure 7A ). Next, we quantified Ca 2+ influx after T cell activation, as calcineurin is known to be activated by Ca 2+ . Although calcium influx was similar in young and old CD4 + T cells in the absence of TAC treatment, the addition of TAC to the culture resulted in a prominent suppression of Ca 2+ influx in an age-specific fashion ( Figure 7B TAC does not promote prolonged allograft survival in old recipients via CD8 + T cells Although our data suggest that TAC alters CD4 + T cell differentiation and cytokine production, it is well established that CD8 + T cells play a critical role in alloimmune responses and graft rejection as well (19) . Indeed, CD8 + T cells have been shown to be able to mediate graft rejection in the absence of CD4 + T cells (28) . Thus, ) from young and old C57BL/6 recipients were co-cultured with anergic, mitomycin-treated DBA/2 splenocytes (A). After 48 h, frequencies of IFNc + CD4 + T cells were measured by ELISPOT. Skin allografts from young DBA mice were transplanted onto young and old C57BL/6 mice (young mice received 0.5 mg/kg TAC, old mice 0.25 mg/kg TAC). By day 6, CD4 + T cells were isolated and stimulated for 4 h. CD4 + T cells were analyzed for IL-10 and IFNc production by flow cytometry (B and C). Statistics: n ≥ 5; mean AE SD; *p < 0.05, **p < 0.001. Mann-Whitney U test was used to compare groups. + T cells were cultured under Th1-polarizing conditions (50 ng/mL recombinant mouse IL-2, 50 ng/mL recombinant mouse IL-12 and 10 lg/mL anti-mouse Il-4; eBioscience). By 96 h, (A) IFNc and (B) IL-10 production were measured by flow cytometry and ELISA. Statistics: n ≥ 5; mean AE SD; *p < 0.05, **p < 0.001. MannWhitney U test was used to compare groups.
we next investigated the role of TAC on CD8 + T cells and allograft survival by depleting CD8 + T cells in recipient animals. Intravenous administration of 100 lg a-CD8 every other day reliably depleted CD8 + T cells (Figure 8 ). While effects of TAC treatment on graft survival in young and old control groups were consistent with our initial experiments (Figure 1) , depletion of CD8 + T cells in TACtreated young and old recipients did not alter age-specific differences in graft survival (Figure 8 ). Taken together, these results suggest that prolonged graft survival in old recipient animals after TAC administration is not mediated by CD8 + T cells. ) from young and old C57BL/6 recipients of DBA/2 skin allografts were collected 6 days after transplantation; mice received trough level adjusted TAC (young mice received 0.5 mg/kg TAC and old mice 0.25 mg/kg TAC). Splenocytes were co-cultured with anergic DBA/2 splenocytes. By 48 h, IL-2 secretion was assessed by ELISPOT (A). CD4 + T cells were isolated and stimulated with PMA/ionomycin/ Brefeldin A for 4 h. IL-2 secretion was measured by flow cytometry and ELISA (B). Statistics: n ≥ 5; mean AE SD; *p < 0.05, **p < 0.001. Mann-Whitney U test was used to compare groups. ) from young and old C57BL/6 recipients of DBA/2 skin allografts were collected 7 days after transplantation; mice received trough level-adjusted TAC (young mice received 0.5 mg/kg TAC and old mice 0.25 mg/kg TAC). Afterward, total splenocytes were cultured with (i) LPS (10 ng/mL), (ii) LPS (10 ng/mL) and treated with 5 ng/mL TAC or (iii) media alone and proliferation was determined by CFSE staining. After 72 h, cells were analyzed by flow cytometry. Statistics: n ≥ 5; mean AE SD; *p < 0.05. Mann-Whitney U test was used to compare groups.
Calcineurin levels and Ca
2+ influx are significantly reduced in old human CD4 + T cells Our results indicated that TAC alters calcineurin levels and Ca 2+ influx known to play a central role in T cell activation. Therefore, we set out to explore the relevance of our findings in human CD4 + cells Here, we assessed na€ ıve CD4 human volunteers and cultured those cells under Th1-polarizing conditions and in the presence of a-CD3/ a-CD28. While calcineurin levels in control (PBS-treated) groups were comparable, old human na€ ıve CD4 + T cells treated with TAC revealed a significantly reduced concentration of calcineurin ( Figure 7C) . Moreover, the addition of TAC to the culture resulted in a dramatically reduced influx of Ca 2+ in old T cells ( Figure 7D ). These experiments show that TAC regulates Ca 2+ influx and calcineurin levels in both murine and human CD4 + T cells in an age-specific manner, emphasizing the clinical relevance of our findings.
Discussion
It is well established that aging has broad effects on all immune compartments. Moreover, we and others have reported that immunosenescence affects alloimmune responses after organ transplantation (29, 30) . Although rejection rates are less frequent in older patients (13) , little is known about age-specific aspects of established immunosuppressants. Yet, age-specific concepts of immunosuppression are of clinical significance as the majority of renal transplant recipients are older than 50 years. + T cells. Skin allografts from young DBA mice were transplanted onto young and old C57BL/6 mice and treated with trough level-adjusted TAC levels (young mice received 0.5 mg/kg TAC and old mice 0.25 mg/kg TAC). Mice received either a-CD8 (100 lL in 1 mL) or carrier solution (PBS 1 mL) intraperitoneally every other day after transplantation and graft survival was monitored (A). After 7 days, splenocytes were collected and frequencies of CD4 + and CD8 + T cells were measured using flow cytometry (B). Representative plots of n = 5 per group are shown. Statistics: *p < 0.05; **p < 0.01. Log-rank test was used to compare graft survival. + T cells from young and old mice were cultured in Th1-polarizing conditions and in the presence of a-CD3/a-CD28. By 96 h, intracellular concentration of calcineurin was measured by sandwich ELISA (Cloud-Clone Corp.) (A). For measurement of Ca 2+ influx, isolated na€ ıve CD4 + T cells from young and old mice were cultured in Th1-polarizing conditions and in the presence of a-CD3/a-CD28 for 96 h and treated or not with TAC (5 ng/mL). Cells were dyed with a fluorescent Ca 2+ calcium indicator (Fluo-4 NW Calcium Assay Kit; Molecular Probes) and then stimulated with PMA/ionomycin including Brefeldin A (Biolegend) and subsequently analyzed with a fluorescence reader at 494 and 516 nm (B). In addition, isolated na€ ıve CD4 + T cells from young (<30 years) and old (>75 years) volunteers were cultured under Th1-polarizing conditions, in the presence of a-CD3 and a-CD28 with or without TAC (5 ng/mL). By 96 h, the concentration of calcineurin was measured using a cellular calcineurin phosphatase activity assay (C). Next, isolated na€ ıve young and old human CD4 + T cells were cultured under Th1-polarizing conditions and in the presence of a-CD3 and a-CD28 for 96 h with or without TAC (5 ng/mL) and dyed with a fluorescent Ca 2+ calcium indicator (Fluo-4 NW Calcium Assay Kit; Thermo Fisher Scientific). After incubation, cells were stimulated with PMA/ionomycin and fluorescence was read at 495 and 520 nm (D). Statistics: n = 5; mean AE SD; *p < 0.05, **p < 0.01. Mann-Whitney U test was used to compare groups.
In our current study, we were able to show that TAC favors allograft survival in old mice. Pharmacokinetic profiles in our model confirmed the clinical relevance of our model with old mice requiring only half of a weightadapted dose to achieve therapeutic trough levels. These findings are in accordance with previous clinical observations in kidney transplant recipients (14) and strongly support an age-dependent reduction in first-pass effects and hepatic metabolism. Of note, when adjusting the AUC subsequent to therapeutic TAC trough levels, old mice still exhibited a prolonged, although less pronounced, graft survival. To the best of our knowledge, this is a novel finding in the debate on age-specific immunosuppression (29) .
Moreover, TAC more efficiently suppressed proinflammatory cytokine production in old CD4 + T cells. Of relevance, decreased levels of IL-2 have been linked to an intensified control of NFATc1 (31) . Specifically, TAC demonstrated enhanced capacities of suppressing IL-2 in old mice, thus showing antiproliferative capacities on CD4 + T cells. While the critical role of IL-2 in T cell activation has been recognized, this effect appears to be impaired with age. Moreover, reduced CD4 proliferation can be restored by exogenous IL-2 at comparable rates for young and old CD4 + T cells (32) . Strikingly, TAC was able to suppress old CD4 + IL-2 + T cells more effectively in an age-specific fashion.
It is known that calcineurin activity declines with aging, although these findings have not been associated with changes in calcineurin protein levels (33, 34) . Nevertheless, our data indicate reduced concentrations of calcineurin not only in old murine but also in old human CD4 + T cells. Of note, when measuring cytosolic Ca 2+ concentrations, we found no significant differences between young and old CD4 + T cells. However, when TAC was added in vitro, we detected lower Ca 2+ levels, again in both old human and murine CD4 + T cells, suggesting that aging may render Ca 2+ channels more susceptible to TAC.
In line with an augmented suppression of IL-2 in old mice, antiproliferative capacities of TAC were enhanced in old CD4 + T cells. Although TAC did not affect the composition of CD4 + T cell subpopulations, TAC inhibited cytokine production in an age-specific manner. In line with our previous studies (17, 18) , overall production of IFNc in splenocytes of old animals was significantly reduced compared with their young counterparts, while frequencies of IFNc + CD4 + and CD8 + T cells were significantly elevated in old recipients. Although these findings may appear contradictive at a first glance, production of IFNc increased in parallel with an increased production of IL-10 in old animals. Of note, double-positive CD4 + IFNc + IL-10 + cells, also termed regulatory type 1 cells, display potent immunosuppressive properties and are able to promote allograft survival independently of CD4 + CD25 + Foxp3 + regulatory T cells (24) . Thus, altering the critical balance of IFNc and IL-10 may play a pivotal role in mediating age-specific effects of TAC (32, 35) .
CD8
+ T cells are known to play a central role in alloimmune responses and graft rejection. In our transplant mouse model, CD8 + T cell depletion did not alterprolonged allograft survival in TAC-treated old recipients, suggesting that TAC effects were not CD8 + T cell mediated.
Clearly, further mechanistic studies detailing the interaction of TAC with CD4 + T cells in immunosenescence are needed. Particularly intriguing are our observations of abnormal Ca 2+ /calcineurin pathways in both old human and murine CD4 + T cells. While our human studies need to be expanded, they clearly show the clinical relevance of our findings. Our current experimental series has focused on young and old recipients, omitting studies in a "middle age" group. Of note, previous unpublished results by our group have indicated no differences in alloimmunity between 12-and 18-month-old mice (data not shown).
In summary, our results demonstrate an augmented immunosuppressive capacity of TAC based on agespecific calcineurin activities linked to compromised CD4 + T cell responses that result into a prolonged graft survival in old recipients. These results are of clinical relevance for an age-specific immunosuppression, aiming to be effective while limiting side effects that are particularly prominent in the aging transplant population (36) .
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